Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Semaxanib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR known ✓ | P35968 | 6/20 | 1.00 |
| ▸ | FLT1 known ✓ | P17948 | 3/20 | 1.00 |
| ▸ | FLT4 known ✓ | P35916 | 2/20 | 1.00 |
| ▸ | KIT known ✓ | P10721 | 1/20 | 1.00 |
| ▸ | RET | P07949 | 7/20 | 1.00 |
| ▸ | ALK | Q9UM73 | 5/20 | 1.00 |
| ▸ | FLT3 | P36888 | 3/20 | 1.00 |
| ▸ | PDGFRB | P09619 | 3/20 | 1.00 |
| ▸ | CSF1R | P07333 | 2/20 | 1.00 |
| ▸ | FGFR1 | P11362 | 2/20 | 1.00 |
| ▸ | SRC | P12931 | 2/20 | 1.00 |
| ▸ | FGFR3 | P22607 | 2/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 2/20 | 1.00 |
| ▸ | PDPK1 | O15530 | 2/20 | 1.00 |
| ▸ | MEN1 | O00255 | 1/20 | 1.00 |
| ▸ | NPC1 | O15118 | 1/20 | 1.00 |
| ▸ | GMNN | O75496 | 1/20 | 1.00 |
| ▸ | USP2 | O75604 | 1/20 | 1.00 |
| ▸ | ABL1 | P00519 | 1/20 | 1.00 |
| ▸ | LMNA | P02545 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Semaxanib SCHEMBL19571 | 1.00 | RET (1.00) | RETKDRALKFLT3FLT1 | |
| Semaxanib SCHEMBL29373311 | 1.00 | RET (1.00) | RETKDRALKFLT3FLT1 | |
| Semaxanib SCHEMBL29351025 | 1.00 | RET (1.00) | RETKDRALKFLT3FLT1 | |
| Semaxanib SCHEMBL28266617 | 1.00 | RET (1.00) | RETKDRALKFLT3FLT1 | |
| SCHEMBL32676579 | 0.87 | RET (0.77) | RETKDRALKFLT3FLT1 | |
| SCHEMBL32676595 | 0.87 | RET (0.77) | RETKDRALKFLT3FLT1 | |
| SCHEMBL32676489 | 0.87 | RET (0.77) | RETKDRALKFLT3FLT1 | |
| SCHEMBL5200799 | 0.85 | KDR (0.74) | RETKDRALKFLT3FLT1 | |
| SCHEMBL5200796 | 0.85 | KDR (0.74) | RETKDRALKFLT3FLT1 | |
| SCHEMBL8211131 | 0.84 | RET (0.73) | RETKDRALKFLT3FLT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2000 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230141981-A1 | NOVEL COMPOUNDS AND COMPOSITION FOR TARGETED THERAPY OF KIDNEY-ASSOCIATED CANCERS | Shanghai MICURX Pharmaceuticals Co., Ltd. (CN) | 2023-05-11 | — | — | US | claimed |
| CN-115298198-A | Novel compounds and compositions for targeted therapy of kidney-related cancers | 上海盟科药业股份有限公司 | 2022-11-04 | — | — | CN | claimed |
| EP-2805945-B1 | Amide substituted indazoles as poly(ADP-ribose)polymerase (PARP) inhibitors | MSD ITALIA SRL (IT) | 2019-04-03 | — | — | EP | claimed |
| US-20170172989-A1 | TREATMENT OF CANCERS HAVING RESISTANCE TO CHEMOTHERAPEUTIC AGENTS | BAYER HEALTHCARE LLC (US) | 2017-06-22 | — | — | US | claimed |
| US-20140301976-A1 | NOVEL HYDROXAMATES AS THERAPEUTIC AGENTS | PHARMACYCLICS, INC. | 2014-10-09 | — | — | US | claimed |
| US-8779171-B2 | Hydroxamates as therapeutic agents | PHARMACYCLICS, INC. (US) | 2014-07-15 | — | — | US | claimed |
| US-20130142758-A1 | NOVEL HYDROXAMATES AS THERAPEUTIC AGENTS | PHARMACYCLICS, INC. (US) | 2013-06-06 | — | — | US | claimed |
| EP-1014953-B1 | FORMULATIONS FOR HYDROPHOBIC PHARMACEUTICAL AGENTS | SUGEN INC (US) | 2012-04-25 | — | — | EP | claimed |
| EP-2425830-A1 | Synergistic drug combination for the treatment of cancer | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2012-03-07 | — | — | EP | claimed |
| US-20110293615-A1 | Use of Combination of Anti-Angiogenic Substance and c-kit Kinase Inhibitor | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2011-12-01 | — | — | US | claimed |
| US-20020119198-A1 | Self-emulsifying drug delivery systems for extremely water-insoluble, lipophilic drugs | PHARMACIA & UPJOHN COMPANY | 2002-08-29 | — | — | US | claimed |
| WO-2002064160-A2 | PHARMACEUTICAL COMPOSITIONS WHICH INHIBIT VASCULAR PROLIFERATION AND METHOD OF USE THEREOF | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES, S.A.S. (FR) | 2002-08-22 | — | — | WO | claimed |
| WO-2002020020-A1 | EXEMESTANE AS CHEMOPREVENTING AGENT | PHARMACIA ITALIA S.P.A. (IT) | 2002-03-14 | — | — | WO | claimed |
| US-20010012844-A1 | Formulations for hydrophobic pharmaceutical agents | SHENOY NARMADA (US) | 2001-08-09 | — | — | US | claimed |
| WO-2001049287-A1 | 3-HETEROARYLIDENYL-2-INDOLINONE COMPOUNDS FOR MODULATING PROTEIN KINASE ACTIVITY AND FOR USE IN CANCER CHEMOTHERAPY | SUGEN, INC. (US) | 2001-07-12 | — | — | WO | claimed |
| US-6248771-B1 | MIXTURE CONTAINING SURFACTANT; ANTIPROLIFERATIVE AGENTS; KINASE INHIBITOR | SUGEN, INC. | 2001-06-19 | — | — | US | claimed |
| EP-0769947-B1 | INDOLINONE COMPOUNDS FOR THE TREATMENT OF DISEASE | SUGEN INC (US) | 2001-05-02 | — | — | EP | claimed |
| EP-1014953-A2 | FORMULATIONS FOR HYDROPHOBIC PHARMACEUTICAL AGENTS | Sugen, Inc. (US) | 2000-07-05 | — | — | EP | claimed |
| WO-1998038984-A2 | FORMULATIONS FOR HYDROPHOBIC PHARMACEUTICAL AGENTS | SUGEN, INC. (US) | 1998-09-11 | — | — | WO | claimed |
| US-5792783-A | CAPABLE OF MODULATING TYROSINE KINASE SIGNAL TRANSDUCTION IN ORDER TO REGULATE, MODULATE AND/OR INHIBIT ABNORMAL CELL PROLIFERATION | SUGEN, INC. (US) | 1998-08-11 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010012844-A1 | Formulations for hydrophobic pharmaceutical agents | ABCG2, SLC7A5, SLCO4C1 | KDR 2394/4885FLT1 2324/4885FLT4 1918/4885 |
| US-20130142758-A1 | NOVEL HYDROXAMATES AS THERAPEUTIC AGENTS | HDAC1, HDAC3, HDAC5 | KDR 4789/4885FLT1 4806/4885FLT4 4688/4885 |
| US-20140301976-A1 | NOVEL HYDROXAMATES AS THERAPEUTIC AGENTS | HDAC1, HDAC3, HDAC5 | KDR 4789/4885FLT1 4806/4885FLT4 4688/4885 |
| US-20170172989-A1 | TREATMENT OF CANCERS HAVING RESISTANCE TO CHEMOTHERAPEUTIC AGENTS | CDK4, TP53, ABCC1 | KDR 2076/4885FLT1 1335/4885FLT4 1122/4885 |
| US-20020119198-A1 | Self-emulsifying drug delivery systems for extremely water-insoluble, lipophilic drugs | LIPA, ABCG2, LIPG | KDR 1068/4885FLT1 1797/4885FLT4 1708/4885 |
| US-20110293615-A1 | Use of Combination of Anti-Angiogenic Substance and c-kit Kinase Inhibitor | KIT, FLT4, KDR | KDR 3/4885FLT1 5/4885FLT4 2/4885 |
| US-20230141981-A1 | NOVEL COMPOUNDS AND COMPOSITION FOR TARGETED THERAPY OF KIDNEY-ASSOCIATED CANCERS | GLS, ATP6V1B1, KRAS | KDR 277/4885FLT1 326/4885FLT4 209/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.